ACA Pharma, Azurity win Macau approvals for Feraheme and Ferabright

By AI, Created 2:40 PM UTC, May 21, 2026, /AGP/ – ACA Pharma and Azurity Pharmaceuticals said Feraheme and Ferabright have both been approved in Macau, opening another route for the ferumoxytol-based products to expand in Greater China. The companies said the approvals support the next phase of hospital engagement and possible participation in the Guangdong-Hong Kong-Macao Greater Bay Area pilot zone.

Why it matters: - The Macau approvals give ACA Pharma and Azurity another regulatory foothold in Asia for two ferumoxytol-based products. - The move could help broaden patient access in Greater China and support future regional commercialization efforts. - Macau may serve as an entry point for broader access initiatives tied to the Greater Bay Area.

What happened: - ACA Pharma and Azurity Pharmaceuticals announced that Feraheme and Ferabright each received regulatory approval in Macau. - Feraheme was approved in Macau on April 2, 2026. - Ferabright was approved in Macau on May 13, 2026. - The announcement was made May 21, 2026.

The details: - ACA Pharma and Azurity said the approvals reflect continued collaboration on regulatory pathways and patient access across Greater China. - Feraheme is an intravenous iron replacement therapy indicated in the U.S. for adult patients with iron deficiency anemia who cannot tolerate oral iron or do not respond well to it, and for adult patients with chronic kidney disease. - Feraheme received U.S. FDA marketing approval in June 2009. - Ferabright is an iron-based contrast agent indicated in the U.S. for MRI of the brain in adults with known or suspected malignant brain neoplasms to visualize lesions with a disrupted blood-brain barrier. - Ferabright uses superparamagnetic iron oxide nanoparticles designed to improve image contrast and help delineate brain tumors compared with non-contrast MRI. - Ferabright is a non-gadolinium alternative and can be used in patients with renal insufficiency in accordance with its approved label. - Ferabright received U.S. FDA marketing approval in October 2025. - ACA Pharma said its Macau Fast-Track platform can enable market entry in as little as 30-90 days in Macau. - ACA Pharma said its Hong Kong Fast-Track pathway for advanced devices can support market entry in about three months in Hong Kong. - ACA Pharma said those hubs can help bridge products into mainland China through the Greater Bay Area and other pilot zones. - Azurity said the company has more than 50 medicines across 10 therapeutic areas and reaches millions of people in more than 50 countries. - ACA Pharma and Azurity are advancing the next phase of regional access efforts, including initial hospital engagement and institutional review processes. - The companies said those efforts are aimed at potential participation in the Guangdong-Hong Kong-Macao Greater Bay Area pilot zone, subject to regulatory, hospital and governmental requirements. - Feraheme and Ferabright are trademarks of Covis Pharma GmbH, a wholly owned subsidiary of Azurity Pharmaceuticals.

Between the lines: - The approvals add momentum to a broader strategy built around Macau as a regulatory gateway into the Greater Bay Area. - The companies are pairing product approvals with hospital-level and institutional review work, which suggests they are preparing for deeper market access rather than stopping at registration. - The release includes forward-looking language about commercialization and access, so the timing and scale of broader regional expansion remain contingent on approvals and local requirements.

What’s next: - ACA Pharma and Azurity plan further hospital engagement and review steps tied to possible Greater Bay Area pilot zone participation. - The companies said future access efforts will depend on applicable regulatory, hospital and governmental requirements. - The release directs additional product information to Feraheme and Ferabright. - ACA Pharma says more information is available at the company’s website and Azurity says more information is available at its website.

The bottom line: - Macau is now a new regulatory beachhead for ACA Pharma and Azurity as they push two ferumoxytol-based products deeper into Asia.